OTCMKTS:EMMA Emmaus Life Sciences Q4 2025 Earnings Report $0.07 0.00 (0.00%) As of 09/18/2026 03:29 PM Eastern ProfileEarnings History Emmaus Life Sciences EPS ResultsActual EPS-$0.03Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AEmmaus Life Sciences Revenue ResultsActual Revenue$3.85 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AEmmaus Life Sciences Announcement DetailsQuarterQ4 2025Date3/30/2026TimeAfter Market ClosesConference Call DateN/AConference Call TimeN/AConference Call ResourcesEarnings HistoryCompany Profile Emmaus Life Sciences Earnings HeadlinesEmmaus Life Sciences Announces Agreement for Evaluation of L-glutamine for Pancreatic CancerAugust 31, 2026 | businesswire.comEmmaus Life Sciences Reports Quarterly Financial ResultsMay 15, 2026 | businesswire.comYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options can give you up to 12 times the leverage of stocks — with a fraction of the capital tied up. This free guide lays it all out in plain English — from A to Z, with step-by-step examples you can follow in your own account. | Profits Run (Ad)Emmaus Life Sciences Reports Annual Financial ResultsMarch 30, 2026 | businesswire.comEmmaus Life Sciences grants NeoImmuneTech Endari distribution rightsDecember 31, 2025 | msn.comEmmaus Life Sciences enters license, distribution agreement with NeoImmuneTechDecember 31, 2025 | msn.comSee More Emmaus Life Sciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Emmaus Life Sciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Emmaus Life Sciences and other key companies, straight to your email. Email Address About Emmaus Life SciencesEmmaus Life Sciences (OTCMKTS:EMMA) is a biopharmaceutical company focused on developing and commercializing treatments for rare diseases and other serious medical conditions. The company’s best-known product is Endari (L-glutamine) oral powder, which was approved by the U.S. Food and Drug Administration in 2017 to reduce acute complications associated with sickle cell disease in adults and children aged five and older. Emmaus has also pursued research programs involving metabolic, gastrointestinal and other rare disorders, including therapies intended to address conditions with limited treatment options. Its activities have included product development, regulatory submissions and commercialization efforts in the United States and selected international markets. The company was founded by physician and researcher Yutaka Niihara, who has served as its chief executive officer and has been closely associated with its sickle cell disease program. Information about Emmaus’ current operations, product portfolio and leadership may change as the company’s business develops.View Emmaus Life Sciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles J.B. Hunt's Stock Plunges After Market Misprices Profit WarningLennar’s Earnings Miss May Be Sending a Bigger Warning About U.S. HousingThese 3 Stocks Sit at the Center of NVIDIA’s Cybersecurity PushGold Has Gone Sideways, But These 3 Stocks Haven’tLennar's Q3 Miss Hides a Stronger Operating Story Beneath the Housing SlumpAeluma’s Selloff Could Be Setting Up Its Next Big MoveBraze Beat Expectations—Now 2 SaaS Peers Are in Focus Upcoming Earnings Cintas (9/23/2026)Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
